D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX)

Context Therapeutics (NASDAQ:CNTX)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They presently have a $9.00 target price on the stock.

Several other research firms also recently commented on CNTX. Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. JMP Securities started coverage on Context Therapeutics in a report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Context Therapeutics in a report on Monday, September 23rd. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $6.33.

Context Therapeutics Stock Performance

Shares of Context Therapeutics stock opened at $0.98 on Wednesday. The stock has a market capitalization of $73.38 million, a PE ratio of -1.08 and a beta of 2.10. Context Therapeutics has a 52 week low of $0.89 and a 52 week high of $2.75. The stock has a 50 day moving average price of $1.38 and a two-hundred day moving average price of $1.89.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.11). Research analysts forecast that Context Therapeutics will post -0.51 EPS for the current year.

Hedge Funds Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Driehaus Capital Management LLC purchased a new stake in shares of Context Therapeutics during the second quarter valued at approximately $4,527,000. Great Point Partners LLC bought a new position in Context Therapeutics in the 2nd quarter valued at $14,876,000. Blue Owl Capital Holdings LP purchased a new stake in shares of Context Therapeutics during the 2nd quarter valued at $10,348,000. State Street Corp raised its stake in shares of Context Therapeutics by 21.5% during the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock worth $219,000 after purchasing an additional 19,800 shares during the period. Finally, Nantahala Capital Management LLC purchased a new position in shares of Context Therapeutics in the 2nd quarter worth about $3,881,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.